ALPS Advisors’s Tonix Pharmaceuticals TNXP Stock Holding History

ALPS Advisors’s Portfolio TNXP Stock Details TNXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1	Closed	-$117K	–	1087
2022 Q1	$117K	Hold	1	–	–	﹤0.01%	823
2021 Q4	$196K	Buy	+1	New	+$318K	﹤0.01%	876

Other funds holding TNXP

Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

ALPS Advisors's TNXP Position: Q2 2022 in Review

ALPS Advisors sold out of Tonix Pharmaceuticals (TNXP) in Q2 2022, closing a stake of 1 share — an estimated $117K sold.

ALPS Advisors first reported a position in TNXP in Q4 2021 and held it in 2 quarters. The position peaked at $196K in Q4 2021. 23 funds tracked by Wall St. Rank hold TNXP as of Q2 2022.

ALPS Advisors reported no remaining Tonix Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
ALPS Advisors sold 1 Tonix Pharmaceuticals share in Q2 2022, an estimated $117K.
ALPS Advisors first reported a position in Tonix Pharmaceuticals in Q4 2021 and held it in 2 quarters.
ALPS Advisors's Tonix Pharmaceuticals position peaked at $196K in Q4 2021.
23 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2022.

Based on ALPS Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.